PAOG Ships First CBD Nutraceutical Product To Distributor Entering $16 Billion Market

Rhea-AI Summary

PAO Group, Inc. (OTC Pink: PAOG) has shipped its first CBD nutraceutical product to a distribution partner, marking its entry into the CBD market. This development stems from the company’s patented cannabis extraction method (U.S. Patent No. 9,199,960). The CBD nutraceuticals market was valued at $5.2 billion in 2020 and is projected to reach $16.4 billion by 2027. PAOG anticipates generating its first revenue in 2021. Further specifics on the product will be announced upon the distribution setup with North American Cannabis Holdings (OTC Pink: USMJ).

Positive

• First CBD nutraceutical product shipped.
• Entering a growing market projected to reach $16.4 billion by 2027.
• Anticipation of first revenue generation in 2021.

Negative

• None.

Sandusky, OH, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced shipping its first CBD nutraceutical product to its distribution partner.

PAOG is developing CBD pharmaceutical and nutraceuticals from its intellectual property associated with a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027.

The shipped product represents PAOG’s first line of CBD nutraceuticals.  The company is on track to generate its first revenue this year, in 2021, since entering the CBD market sector.

PAOG plans to announce specifics about its first CBD nutraceutical product in an upcoming formal product launch announcement once the distributor is set up to begin sales and distribution.

PAOG plans to distribute its nutraceuticals through North American Cannabis Holdings, Inc. (OTC Pink: USMJ). See USMJ’s ecommerce site at www.usmj.com.

PAOG’s CBD nutraceutical developments stem from the company’s long-term CBD pharmaceutical initiative built on a CBD intellectual property acquisition from Nouveau Life Pharmaceuticals (OTC Pink: NOUV).

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

FAQ

What is the significance of the product shipped by PAOG?

The shipment of its first CBD nutraceutical product marks PAOG's entry into the lucrative CBD market.

What is the expected growth of the CBD nutraceuticals market?

The CBD nutraceuticals market is projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027.

When does PAOG expect to generate its first revenue?

PAOG anticipates generating its first revenue in 2021.

Which company is PAOG partnering with for distribution?

PAOG plans to distribute its nutraceuticals through North American Cannabis Holdings, Inc. (OTC Pink: USMJ).

What intellectual property does PAOG utilize for its products?

PAOG is developing its CBD products using a patented cannabis extraction method under U.S. Patent No. 9,199,960.